On June 21, Beijing SL Pharmaceutical Co., Ltd. announced an investment of 40 million yuan in Pro-heal Pharmaceuticals, with a pre-investment valuation of 300 million yuan and a post-investment valuation of 340 million yuan. Beijing SL Pharmaceutical Co., Ltd. holds 11.765% equity in Pro-heal.Beijing SL Pharmaceutical Co., Ltd. to Continue Strategic Cooperation with Pro-heal Pharmaceuticals, investing to support Pro-heal in completing the PHP1003 and PHP0101 projects, including subsequent R&D work such as clinical trials and process validation. Depending on the project progress and investment situation, determine to increase the equity stake in Pro-heal Pharmaceuticals and explore deep cooperation in project industrialization and commercialization.This clause basically indicates that Pro-heal is selling itself.Beijing SL Pharmaceutical Co., Ltd.）
The core team members of Pro-heal Pharmaceuticals are composed of several returned overseas PhDs who have worked in well-known foreign pharmaceutical companies. Pro-heal Pharmaceuticals has comprehensively laid out innovative drug research and development for ophthalmic and autoimmune diseases with novel mechanisms of action, particularly demonstrating strong advantages in the development of new drugs for immune-related eye diseases. Currently, Pro-heal Pharmaceuticals has several projects advancing to the preclinical research and clinical trial stages, among which...PHP1003 Injection, a drug for treating thyroid-associated ophthalmopathy, has entered Phase II clinical trials, marking it as the first self-developed innovative drug in China for this condition. PHP0101 Eye Drops, a small-molecule eye drop for presbyopia treatment, is currently in Phase I clinical trials. PHP0003 Eye Drops, a small-molecule formulation for retinal diseases, is in the preclinical CMC stage. PHP1212, which can be used to treat various autoimmune diseases, is also in the preclinical CMC stage.In addition, Pro-heal Pharmaceuticals has also built multiple technology platforms and developed a product pipeline in other ophthalmic treatment fields, especially with a distinctive layout in the drug pipeline for rare diseases. It is expected to become a leading enterprise in the development of innovative drugs for ophthalmology and autoimmune disease treatment.Pro-healPro-heal Pharmaceuticals completed its Angel Round of financing in August 2019 (led by Shanghai Guohong Zhiyan Venture Investment Partnership (Limited Partnership)) and its Pre-A Round of financing in March 2021 (co-led by YuanSheng Ventures and HaiSong Capital). Pro-heal Pharmaceuticals has been recognized as a leading enterprise in Suzhou Industrial Park, a Gusu Leading Talent Enterprise in Suzhou City, and a Jiangsu Province Innovation and Entrepreneurship Talent Enterprise.
Follow the official account below to see the world!
